New Launch19 Mar 2026, 09:33 am
Glenmark Pharmaceuticals Inc., USA Launches Authorized Generic to Milnacipran Hydrochloride Tablets with $102.9 Million Market
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. This launch signifies the company's commitment to bring quality and affordable alternatives to patients. According to IQVIA™ sales data for the 12-month period ending January 2026, the Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market achieved annual sales of approximately $102.9 million. Glenmark's product is only approved for the indications listed in Glenmark’s approved label.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA launches Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
- The authorized generic to Savella® Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
- The Savella® Tablets market achieved annual sales of approximately $102.9 million
- Strengthens Glenmark's commitment to bring quality and affordable alternatives for patients
- Glenmark's product is only approved for the indications listed in Glenmark’s approved label